These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2623030)

  • 1. Centrally administered CCK-8 suppresses activity in mice by a "peripheral-type" CCK receptor.
    Britton DR; Yahiro L; Cullen MJ; Kerwin JF; Kopecka H; Nadzan AM
    Pharmacol Biochem Behav; 1989 Dec; 34(4):779-83. PubMed ID: 2623030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice.
    Hirosue Y; Inui A; Teranishi A; Miura M; Nakajima M; Okita M; Nakajima Y; Himori N; Baba S; Kasuga M
    Am J Physiol; 1993 Sep; 265(3 Pt 2):R481-6. PubMed ID: 8214137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.
    Hirosue Y; Inui A; Miura M; Nakajima M; Okita M; Himori N; Baba S; Kasuga M
    Peptides; 1992; 13(1):155-7. PubMed ID: 1620653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism.
    Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
    Millington WR; Mueller GP; Lavigne GJ
    J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo.
    Miller TR; Bianchi BR; Witte DG; Lin CW
    Regul Pept; 1993 Jan; 43(1-2):107-12. PubMed ID: 8426907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A behavioural pharmacological study on intracerebroventricularly administered CCK-8 related peptides in mice.
    Hagino Y; Moroji T; Iizuka R
    Neuropeptides; 1989; 13(2):107-13. PubMed ID: 2739882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking of cholecystokinin octapeptide behavioral effects by proglumide.
    Katsuura G; Hsiao S; Itoh S
    Peptides; 1984; 5(3):529-34. PubMed ID: 6089145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cataleptogenic and anticataleptic activity produced by cholecystokinin octapeptides in mice.
    Kádár T; Borda L; Penke B; Kovács K; Telegdy G
    Neuropeptides; 1985 Jun; 6(3):259-68. PubMed ID: 4040614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.
    Rex A; Barth T; Voigt JP; Domeney AM; Fink H
    Neurosci Lett; 1994 May; 172(1-2):139-42. PubMed ID: 8084519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversed behavioral effect of cholecystokinin after frontal decortication in rats.
    Itoh S; Katsuura G; Itoh T; Morimoto T
    Life Sci; 1994; 55(11):PL213-6. PubMed ID: 8072383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholecystokinin receptor subtypes and neuromodulation.
    Altar CA
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):381-93. PubMed ID: 2748871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraventricular CCK-8 reduces single meal size in the baboon by interaction with type-A CCK receptors.
    Figlewicz DP; Nadzan AM; Sipols AJ; Green PK; Liddle RA; Porte D; Woods SC
    Am J Physiol; 1992 Oct; 263(4 Pt 2):R863-7. PubMed ID: 1415799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A-71623, a selective CCK-A receptor agonist, suppresses food intake in the mouse, dog, and monkey.
    Asin KE; Bednarz L; Nikkel AL; Gore PA; Nadzan AM
    Pharmacol Biochem Behav; 1992 Aug; 42(4):699-704. PubMed ID: 1513850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain CCK-B receptors mediate the suppression of dopamine release by cholecystokinin.
    Altar CA; Boyar WC
    Brain Res; 1989 Apr; 483(2):321-6. PubMed ID: 2706523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential startle reactivity following central CCK-8S and systemic Boc CCK-4 administration in mice: antecedent stressor history and testing condition.
    Hebb AL; Zacharko RM; Bowie JP; Drolet G
    Behav Neurosci; 2003 Aug; 117(4):704-15. PubMed ID: 12931956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response.
    Felicio LF; Mazzini BK; Cacheiro RG; Cruz TN; Flório JC; Nasello AG
    Peptides; 2001 Aug; 22(8):1299-304. PubMed ID: 11457524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral effects of cholecystokinin and its related peptides in rats.
    Itoh S; Katsuura G
    Prog Clin Biol Res; 1985; 192():139-45. PubMed ID: 2934743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.
    Johnson NJ; Rodgers RJ
    Psychopharmacology (Berl); 1996 Apr; 124(4):355-64. PubMed ID: 8739551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.